MIPI Alliance Releases MIPI CCS, a New Specification that Streamlines Integration of Image Sensors in Mobile Devices
The MIPI® Alliance, an international organization that develops interface specifications for mobile and mobile-influenced industries, today released a new specification that provides a standardized way to integrate image sensors in mobile-connected devices.
The new specification, MIPI Camera Command Set v1.0 (MIPI CCS v1.0), defines a standard set of functionalities for implementing and controlling image sensors. The specification is offered for use with MIPI Camera Serial Interface 2 v2.0 (MIPI CSI-2 v2.0) and is now available for download. In an effort to help standardize use of MIPI CSI-2, MIPI Alliance membership is not required to access the specification.
MIPI CSI-2 is the industry’s most widely used hardware interface for deploying camera and imaging components in mobile devices. The introduction of MIPI CCS to MIPI CSI-2 further increases interoperability, and reduces integration and costs for complex imaging and vision systems.
“MIPI Alliance is building on its success in the mobile camera and imaging ecosystem with MIPI CCS, a new specification that will enhance the market-enabling conveniences MIPI CSI-2 already provides,” said Joel Huloux, chairman of MIPI Alliance. “The availability of MIPI CCS will help image sensor vendors promote greater adoption of their technologies and it will help developers accelerate time-to-market with innovative designs targeting the mobile industry, connected cars, the Internet of Things, AR/VR and other areas.”
From startups to global organizations, companies are integrating image sensor components into their designs for specialized and mass-market products. To date, image sensor integration has required device-specific software to enable basic operations. As imaging applications have become more sophisticated and manufacturers have begun deploying multiple image sensors in their products, implementation has become more complex and time consuming.
MIPI CCS alleviates these challenges by making it possible to craft a common software driver to configure the basic functionalities of any off-the-shelf image sensor that is compliant with MIPI CCS and MIPI CSI-2 v2.0. The new specification provides a complete command set that can be used to integrate basic image sensor features such as resolution, frame rate and exposure time, as well as advanced features like phase detection auto focus (PDAF), single frame HDR or fast bracketing.
“The overall advantage of MIPI CCS is that it will enable rapid integration of basic camera functionalities in plug-and-play fashion without requiring any device-specific drivers, which has been a significant pain point for developers,” said Mikko Muukki, technical lead for MIPI CCS. “MIPI CCS will also give developers flexibility to customize their implementations for more advanced camera and imaging systems.”
MIPI CCS v1.0 was developed for use with MIPI CSI-2 v2.0 and, as such, is backward compatible with earlier versions of the MIPI CSI-2 interface. It is implemented on either of two physical layers from MIPI Alliance: MIPI C-PHY or MIPI D-PHY.
Join the MIPI CCS v1.0 Webinar
Developers are invited to attend a webinar “Introduction to MIPI Camera Command Set v1.0” on 10 January at 11 a.m. EST, 8 a.m. PST. For information and registration, please go to: http://bit.ly/2jMIp2g.
To discover more about MIPI Alliance and to connect with its social networks, follow its Twitter page, join its LinkedIn group and like its Facebook page. To join MIPI Alliance, use the Join MIPI link on the organization’s site.
About MIPI Alliance
MIPI Alliance (MIPI) develops interface specifications for mobile and mobile-influenced industries. There is at least one MIPI specification in every smartphone manufactured today. Founded in 2003, the organization has 300 member companies worldwide and 13 active working groups delivering specifications within the mobile ecosystem. Members of the organization include handset manufacturers, device OEMs, software providers, semiconductor companies, application processor developers, IP tool providers, test and test equipment companies, as well as camera, tablet and laptop manufacturers. For more information, please visit www.mipi.org.
MIPI® is a registered trademark owned by MIPI Alliance. MIPI CSI-2SM v2.0, MIPI CCS SM, MIPI C-PHYSM and MIPI D-PHYSM are service marks of the MIPI Alliance.
Interprose for MIPI Alliance
Lisa McCausland, +1 303-888-2137
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme tältä julkaisijalta, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
OTEZLA® (Apremilast) Phase III Data Showed Significant Improvements in Patients with Active Behçet’s Disease with Oral Ulcers18.2.2018 00:00 | Tiedote
Celgene Corporation (NASDAQ:CELG) today announced that data from the phase III RELIEF™ clinical trial of OTEZLA® (apremilast) in patients with active Behçet’s Disease with oral ulcers were presented in a late-breaking oral presentation at the 2018 American Academy of Dermatology (AAD) Annual Meeting. The results showed statistically significant reductions in oral ulcers with apremilast 30 mg twice daily (BID) versus placebo through week 12. OTEZLA (apremilast) is Celgene’s oral selective inhibitor of phosphodiesterase 4 (PDE4). Behçet’s Disease is a rare, chronic, multi-system inflammatory syndrome. Oral ulcers, the most common manifestation of Behçet’s Disease, can be disabling and have a substantial effect on quality of life. This study primarily evaluated the effect of apremilast on recurring oral ulcers in patients with active Behçet’s Disease who were previously treated with at least one topical or systemic medication. “Reducing oral ulcers, which are painful and can negatively im
CT-P13 (biosimilar infliximab) is comparable to reference infliximab and adalimumab in highly anticipated real-world study17.2.2018 11:00 | Tiedote
Twelve-month data from the Personalised Anti-TNF therapy in Crohn’s disease Study (PANTS) was presented at the 13th Congress of the European Crohn’s and Colitis Organisation (ECCO). The results indicate that the clinical effectiveness, safety and immunogenicity of Celltrion Healthcare’s CT-P13 (biosimilar infliximab) in patients with Crohn’s disease (CD) is comparable to those treated with reference infliximab as well as those treated with adalimumab.1 The UK-wide, three-year prospective observational study investigated primary non-response (PNR), loss of response (LOR) and adverse drug reactions (ADR) to infliximab (reference infliximab and CT-P13) and adalimumab in 1610 CD patients. The data show comparable efficacy between CT-P13, reference infliximab and adalimumab in relation to PNR, LOR and ADR rates. In addition, at week 54, the remission rate was 39.7%, 39.0% and 32.7% for reference infliximab, CT-P13 and adalimumab treated patients, respectively.1 The PANTS study investigates
Avanti Communications HYLAS 4 Satellite Arrives in French Guiana16.2.2018 21:26 | Tiedote
Avanti Communications Group plc (“Avanti”), a leading provider of satellite data communications services in Europe, the Middle East and Africa (“EMEA”), announces its HYLAS 4 satellite has arrived safely in French Guiana ahead of its March 2018 launch. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180216005586/en/ Avanti Communications HYLAS 4 Satellite Arrives in French Guiana (Photo: Business Wire) The spacecraft, built by Orbital ATK was packed and shipped at their Satellite Manufacturing Facility in Dulles, Virginia, United States and flown to French Guiana, where it was unloaded and will be taken to the Arianespace launch facilities in Kourou. HYLAS 4 uses the latest High Throughput Satellite technology, doubling Avanti's Ka-band capacity across EMEA. The latest addition to Avanti's HYLAS fleet will provide: Backhaul services for mobile network operators Wholesale broadband for ISPs Connectivity for governments (civil a
General Cable Corporation Stockholders Approve Acquisition By Prysmian Group16.2.2018 20:05 | Tiedote
General Cable Corporation (NYSE: BGC) today announced the voting results from the Company’s special meeting of stockholders held this morning. Stockholders of General Cable approved the Company’s previously announced acquisition by Prysmian Group (BIT: PRY) for $30.00 per share in cash. A total of 38,140,754 shares, representing approximately 75.34% of the total number of shares of common stock outstanding and approximately 99% of the total votes cast, were voted in favor of the merger. Subject to regulatory approvals and other customary closing conditions, the transaction is expected to close by the third quarter of 2018. About General Cable General Cable (NYSE:BGC), with headquarters in Highland Heights, Kentucky, is a global leader in the development, design, manufacture, marketing and distribution of aluminum, copper and fiber optic wire and cable products for the energy, communications, automotive, industrial, construction and specialty segments. General Cable is one of the larges
Systemic Sclerosis World Congress:Inspirational Patient Stories Reveal the Challenging Realities of Living with Devastating Rare Disease16.2.2018 12:03 | Tiedote
Boehringer Ingelheim today unveils a new phase of 'More Than Scleroderma: The Inside Story', and launches the new patient website www.morethanscleroderma.com. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180216005188/en/ Anna, 36, living with scleroderma (Photo: Business Wire) The global initiative highlights the importance of understanding the ‘inside story’ of each individual living with scleroderma, also known as systemic sclerosis. To coincide with the Systemic Sclerosis World Congress in Bordeaux, 15-17 February 2018, new and truly inspiring patient stories are revealed, reflecting the real-life, diverse and very moving journeys of people living with scleroderma across the world. The campaign will also be launched in the U.S. The new website www.morethanscleroderma.com features a powerful collection of photographs and video stories of people living with scleroderma across the world, revealing the life-changing impact o
Philip Morris International Recognized as a Global Top Employer for the Second Year in a Row16.2.2018 11:00 | Tiedote
Philip Morris International Inc. (PMI) (NYSE/Euronext Paris: PM) today is recognized for the second year in a row as a Global Top Employer. This year’s certification from the Top Employer Institute is awarded to PMI teams in 44 countries, a testament to the company’s consistency and excellence in offering an enriching and dynamic work environment, and exceptional development opportunities for employees across the globe. PMI has been recognized by the Top Employer Institute for six consecutive years. This year, PMI was awarded with five regional certifications in Europe, the Middle East, Africa and, for the first time, in North America and Latin America. Additionally, Indonesia was the first PMI affiliate to be certified in Asia. “It is a proud moment for all of us at PMI,” said Charles Bendotti, PMI Senior Vice President, People and Culture. “Our success as a company relies on the men and women who come to work every day with a passion to achieve, and a willingness to learn, grow, and
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme